BOSTON--(BUSINESS WIRE)--Cerevel Therapeutics, a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced the appointment of Bryan K. Phillips as chief legal officer. Mr. Phillips is an accomplished legal executive and joins Cerevel Therapeutics with over 15 years of corporate experience in the healthcare industry. He most recently served as the senior vice president, legal, human resources and information technology, general counsel and secretary for Surmodics, Inc., a Minnesota-based publicly-traded medical technology company. He will join the leadership team on December 2, 2019.
“Bryan is an expert in a broad-range of legal and business matters and brings a wealth of knowledge and experience to Cerevel Therapeutics as we continue the build out of our senior leadership team,” said Tony Coles, M.D., chief executive officer and chairperson of Cerevel Therapeutics. “His demonstrated success as a legal and corporate executive will help guide Cerevel Therapeutics into its next phase of growth.”
“I am thrilled to join Cerevel Therapeutics and work alongside this talented team to advance the development of new therapies for devastating neuroscience diseases,” said Mr. Phillips. “I look forward to supporting the effort to bring therapies to those patients who have been in need for far too long.”
About Bryan K. Phillips
Mr. Phillips is the former senior vice president, legal, human resources and information technology, general counsel and secretary for Surmodics, Inc., a publicly-traded medical technology company headquartered in Eden Prairie, Minnesota. Prior to joining Surmodics in 2005, Phillips served as patent counsel at Guidant Corporation’s Cardiac Rhythm Management Group (now part of Boston Scientific). Phillips began his legal career at a Minneapolis-based intellectual property law firm.
Phillips is active in the Twin Cities community, having served on numerous non-profit boards. He currently serves as chair of the board of trustees for the Science Museum of Minnesota, and as a trustee of Minnesota Public Radio. Phillips earned a bachelor’s degree in mechanical engineering from the University of Kansas and a law degree from the University of Minnesota Law School.
About Cerevel Therapeutics
Cerevel Therapeutics is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company seeks to unlock the science surrounding new treatment opportunities through understanding the neurocircuitry of neuroscience diseases and associated symptoms. Cerevel Therapeutics has a diversified pipeline comprising five clinical-stage investigational therapies and several pre-clinical compounds with the potential to treat a range of neuroscience diseases, including Parkinson’s, epilepsy, schizophrenia and substance use disorders. Headquartered in Boston, Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations or potential acquisitions. For more information, visit www.cerevel.com.
Special Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, statements about the potential of our research and development programs and the potential attributes and benefits of our product candidates. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.
